Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 15, 2019. The filing addresses a corporate governance event regarding a Special Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a procedural corporate event and contains no financial statement data.
Material Changes
The primary material event is the adjournment of the Special Meeting of Stockholders originally scheduled for January 15, 2019. The meeting was adjourned because holders of a sufficient number of outstanding common stock had not yet submitted proxies to indicate their votes. The Company requires additional time to collect the necessary votes.
Outlook and Management Commentary
- Rescheduled Meeting: The Special Meeting will resume at 9:00 a.m. PST on February 12, 2019.
- Location: The meeting will be held at the Company's offices at 11055 Flintkote Avenue, San Diego, California 92121.
- Proxy Solicitation: The Company will continue to solicit proxies from stockholders during the adjournment period.
- Voting Eligibility: Only stockholders of record on the record date of December 14, 2018 are entitled to vote.
Key Facts for Investor Verification
- Verify the rescheduled date of the Special Meeting (February 12, 2019) and confirm the location.
- Confirm the record date for voting eligibility (December 14, 2018).
- Review the press release furnished as Exhibit 99.1 for additional details on the adjournment.
- Note that this filing contains no financial performance data or guidance.